Insider Selling: Insulet (NASDAQ:PODD) SVP Sells 687 Shares of Stock

Key Points

• Insulet Corporation's SVP Prem Singh sold 687 shares at an average price of $347.49, reducing their position by 16.58%, now holding 3,456 shares valued at approximately $1.2 million.
• The company's stock price increased by 0.9% to $352.82, with a one-year range from $217.82 to $353.50.
• Insulet recently reported earnings of $1.17 per share, surpassing analysts' expectations, and experienced a 32.9% year-over-year revenue growth, totaling $649.10 million for the quarter.

Insulet Corporation (NASDAQ:PODD - Get Free Report) SVP Prem Singh sold 687 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Insulet Stock Up 0.9%

Shares of PODD stock traded up $3.26 during midday trading on Tuesday, reaching $352.82. 656,705 shares of the stock were exchanged, compared to its average volume of 751,713. Insulet Corporation has a 1 year low of $217.82 and a 1 year high of $353.50. The company's 50 day moving average is $308.26 and its two-hundred day moving average is $290.34. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a market cap of $24.83 billion, a PE ratio of 107.24, a price-to-earnings-growth ratio of 2.92 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the prior year, the business earned $0.55 EPS. The business's revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Institutional Investors Weigh In On Insulet

Institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its stake in Insulet by 55.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after buying an additional 1,867 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Insulet by 85.1% in the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after buying an additional 412 shares in the last quarter. QRG Capital Management Inc. increased its stake in Insulet by 75.6% in the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock worth $533,000 after buying an additional 874 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Insulet by 225.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock worth $408,000 after buying an additional 1,075 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its stake in Insulet by 2.6% in the 1st quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier's stock worth $2,156,000 after buying an additional 210 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PODD. Canaccord Genuity Group boosted their price target on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Truist Financial began coverage on Insulet in a research report on Monday, June 16th. They issued a "buy" rating and a $365.00 price target on the stock. Finally, Raymond James Financial reissued an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Sixteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and an average target price of $335.12.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.